FluoroPharma Medical, Inc.: 10-Q filed 2013-11-14
What FluoroPharma Medical, Inc. reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 24 published measures, 73 facts as tagged in accession 0001415889-13-002325.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-14
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001415889-13-002325 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All FluoroPharma Medical, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,612,636 | USD | |
| At 2012-12-31 | 1,613,534 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 788,310 | USD | |
| At 2012-12-31 | 1,378,027 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 122,935 | USD | |
| At 2012-12-31 | 1,304,088 | USD | |
| At 2012-09-30 | 776,163 | USD | |
| At 2011-12-31 | 3,265,141 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -1,102,627 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -3,191,593 | USD | 273 |
| 2003-12-13 to 2013-09-30 | -18,936,800 | USD | 3580 |
| 2012-07-01 to 2012-09-30 | -998,996 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -2,662,979 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -2,001,232 | USD | 273 |
| 2003-12-13 to 2013-09-30 | -13,161,217 | USD | 3580 |
| 2012-01-01 to 2012-09-30 | -2,450,543 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 2,046 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 415,018 | USD | 3580 |
| 2012-01-01 to 2012-09-30 | 38,435 | USD | 274 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 808,185 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 13,846,770 | USD | 3580 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 11,894 | USD | 273 |
| 2003-12-13 to 2013-09-30 | -562,618 | USD | 3580 |
| 2012-01-01 to 2012-09-30 | -38,435 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -21,580,114 | USD | |
| At 2012-12-31 | -16,890,540 | USD |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -0.1 | USD/shares | 92 |
| 2013-01-01 to 2013-09-30 | -0.19 | USD/shares | 273 |
| 2003-12-13 to 2013-09-30 | -2.05 | USD/shares | 3580 |
| 2012-07-01 to 2012-09-30 | -0.05 | USD/shares | 92 |
| 2012-01-01 to 2012-09-30 | -0.12 | USD/shares | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 164,946 | USD | |
| At 2012-12-31 | 176,889 | USD |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 3,396,874 | USD | |
| At 2012-12-31 | 1,381,398 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 33,974 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 50,620 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 366,946 | USD | 3580 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 2,824,326 | USD | |
| At 2012-12-31 | 235,507 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 408,233 | USD | |
| At 2012-12-31 | 137,779 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 50,816 | USD | |
| At 2012-12-31 | 55,247 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 897,136 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 3,040,190 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 20,017,630 | USD | 3580 |
| 2012-07-01 to 2012-09-30 | 1,008,334 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 2,796,691 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 322,942 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 979,675 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 7,046,738 | USD | 3580 |
| 2012-07-01 to 2012-09-30 | 344,871 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 905,142 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 24,390,013 | shares | |
| At 2012-12-31 | 24,330,013 | shares |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -2,510,887 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 21,580,114 | USD | 273 |
| 2012-07-01 to 2012-09-30 | -1,041,717 | USD | 92 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 574,194 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 2,060,515 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 12,970,892 | USD | 3580 |
| 2012-07-01 to 2012-09-30 | 663,463 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,891,549 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -205,491 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -151,403 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 1,080,830 | USD | 3580 |
| 2012-07-01 to 2012-09-30 | 9,338 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 133,712 | USD | 274 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2003-12-13 to 2013-09-30 | 50,000 | USD | 3580 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 277,048 | USD | 273 |
| 2003-12-13 to 2013-09-30 | 927,077 | USD | 3580 |
| 2012-01-01 to 2012-09-30 | -114,336 | USD | 274 |
Inspect the source
- Entity
- FluoroPharma Medical, Inc. / CIK 0001402785
- Captured
- SEC response SHA-256
4d77d986a03178d60883d667e91c227ed829415c26872c73ee7ae0df9851ff14
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001402785.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))